247 related articles for article (PubMed ID: 20107296)
1. Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.
Seo HJ; Sohi MS; Patkar AA; Masand PS; Pae CU
Postgrad Med; 2010 Jan; 122(1):125-38. PubMed ID: 20107296
[TBL] [Abstract][Full Text] [Related]
2. Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder.
Perry R; Cassagnol M
Clin Ther; 2009 Jun; 31 Pt 1():1374-404. PubMed ID: 19698900
[TBL] [Abstract][Full Text] [Related]
3. Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.
Kamath J; Handratta V
Expert Rev Neurother; 2008 Dec; 8(12):1787-97. PubMed ID: 19086875
[TBL] [Abstract][Full Text] [Related]
4. Desvenlafaxine in the treatment of major depressive disorder.
Pae CU
Expert Opin Pharmacother; 2011 Dec; 12(18):2923-8. PubMed ID: 22098230
[TBL] [Abstract][Full Text] [Related]
5. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
6. Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.
Reddy S; Kane C; Pitrosky B; Musgnung J; Ninan PT; Guico-Pabia CJ
Curr Med Res Opin; 2010 Jan; 26(1):139-50. PubMed ID: 19919295
[TBL] [Abstract][Full Text] [Related]
7. Desvenlafaxine: a new antidepressant or just another one?
Pae CU
Expert Opin Pharmacother; 2009 Apr; 10(5):875-87. PubMed ID: 19351235
[TBL] [Abstract][Full Text] [Related]
8. [Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine].
Lilue M; Palacios S
Ginecol Obstet Mex; 2009 Oct; 77(10):475-81. PubMed ID: 19902676
[TBL] [Abstract][Full Text] [Related]
9. Desvenlafaxine succinate for the treatment of major depressive disorder.
Lohoff FW; Rickels K
Expert Opin Pharmacother; 2008 Aug; 9(12):2129-36. PubMed ID: 18671467
[TBL] [Abstract][Full Text] [Related]
10. The role of venlafaxine in rational antidepressant therapy.
Feighner JP
J Clin Psychiatry; 1994 Sep; 55 Suppl A():62-8; discussion 69-70, 98-100. PubMed ID: 7961545
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME
J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause.
Archer DF; Seidman L; Constantine GD; Pickar JH; Olivier S
Am J Obstet Gynecol; 2009 Feb; 200(2):172.e1-10. PubMed ID: 19110224
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
Speroff L; Gass M; Constantine G; Olivier S;
Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
[TBL] [Abstract][Full Text] [Related]
14. Identifying meaningful differences in vasomotor symptoms among menopausal women.
Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and Norepinephrine Reuptake Inhibitors.
Shelton RC
Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
17. Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause.
Pae CU; Park MH; Marks DM; Han C; Patkar AA; Masand PS
Curr Opin Investig Drugs; 2009 Jan; 10(1):75-90. PubMed ID: 19127490
[TBL] [Abstract][Full Text] [Related]
18. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.
Cowen PJ; Ogilvie AD; Gama J
Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202
[TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
